Watchlist Price Alert

Gilead Sciences Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD

103.64

0.39 (0.38%)

At close: May 02, 2025, 3:59 PM

104.00

0.35%

After-hours: May 02, 2025, 05:43 PM EDT

0.38% (1D)

Bid	102.62
Market Cap	129.2B
Revenue (ttm)	28.73B
Net Income (ttm)	5.96B
EPS (ttm)	7.74
PE Ratio (ttm)	13.39
Forward PE	12.19
Analyst	Buy

Ask	104
Volume	5,065,404
Avg. Volume (20D)	9,634,825
Open	104.89
Previous Close	103.25
Day's Range	102.47 - 105.17
52-Week Range	62.07 - 119.96
Beta	0.34

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, V...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jan 22, 1992

Employees 17,600

Stock Exchange NASDAQ

Ticker Symbol GILD

Website https://www.gilead.com

Full Company Profile

Analyst Forecast

According to 23 analyst ratings, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 6.14% from the latest price.

Stock Forecasts

Earnings Surprise

Gilead Sciences has released their quartely earnings on Apr 24, 2025:

Revenue of $6.67B misses estimates by $103M, with -0.28% YoY decline.

EPS of 1.81 exceeds estimates by 0.05, with 237.12% YoY growth.

Why Price Moved

1 week ago

-2.81%

Gilead Sciences shares are trading lower after the... Unlock content with Pro Subscription

1 week ago

-0.22%

Gilead Sciences shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 EPS guidance.

News

2 days ago · marketbeat.com

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those...

3 days ago · zacks.com

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure.

3 days ago · zacks.com

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

5 days ago · businesswire.com

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...

5 days ago · reuters.com

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's of...

5 days ago · cnbc.com

Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions

5 days ago · businesswire.com

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10,...

1 week ago · fool.com

Why Gilead Sciences Stock Slipped Today

Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its shar...

1 week ago · zacks.com

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.

1 week ago · seekingalpha.com

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest perfor...

Load More News